{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T22:15:54Z","timestamp":1740176154832,"version":"3.37.3"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T00:00:00Z","timestamp":1597104000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["JA Clin Rep"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>We report a patient in whom we failed to suppress ventricular fibrillation (VF) using nifekalant but succeeded using amiodarone during cardiopulmonary bypass (CPB).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 65-year-old male with hemodialysis complained of dyspnea and was diagnosed with aortic valve stenosis and angina pectoris; he was opted for elective aortic valve replacement. When the aortic forceps were declamped during CPB, immediate VF was observed; several attempts of electrical cardioversion (EC) with lidocaine and landiolol and three administrations of nifekalant were temporarily effective. However, the rhythm subsequently changed to torsades de pointes. We administered 2\u2009g of magnesium sulfate followed by three doses of amiodarone and initiated continuous infusion. Furthermore, we initiated the pacemaker and intra-aortic balloon pumping. These procedures seemed to be effective; the sinus rhythm was sustained until the end of the surgery.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>We experienced a cardiac surgery requiring 16 EC attempts to terminate the life-threatening arrhythmias using amiodarone.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s40981-020-00369-w","type":"journal-article","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T21:08:14Z","timestamp":1597180094000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Refractory ventricular arrhythmias during aortic valve replacement and cardiac artery bypass requiring 16 attempts of electrical cardioversion: a case report"],"prefix":"10.1186","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0052-1020","authenticated-orcid":false,"given":"Mitsuharu","family":"Kodaka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsu","family":"Mori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junko","family":"Ichikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Ando","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makiko","family":"Komori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,11]]},"reference":[{"unstructured":"Guidelines for Drug Treatment of Arrhythmias (JCS 2011) https:\/\/www.jstage.jst.go.jp\/article\/circj\/77\/1\/77_CJ-66-0054\/_pdf (accessed on 5\/6\/2020).","key":"369_CR1"},{"key":"369_CR2","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s00540-013-1775-5","volume":"28","author":"N Harayama","year":"2014","unstructured":"Harayama N, Nihei S, Nagata K, Isa Y, Goto K, Aibara K, et al. Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. J Anesth. 2014;28:587\u201392.","journal-title":"J Anesth"},{"key":"369_CR3","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1097\/FJC.0000000000000310","volume":"66","author":"M Amino","year":"2015","unstructured":"Amino M, Inokuchi S, Nagao K, Nakagawa Y, Yoshioka K, Ikari Y, et al. Nifekalant hydrochloride and amiodarone hydrochloride result in similar improvements for 24-hour survival in cardiopulmonary arrest patients: the SOS-KANTO 2012 study. J Cardiovasc Pharmacol. 2015;66:600\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"key":"369_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1253\/circj.69.1237","volume":"69","author":"T Katoh","year":"2005","unstructured":"Katoh T, Mitamura H, Matsuda N, Takano T, Ogawa S, Kasanuki H. Emergency treatment with nifekalant, a novel class III anti-arrhythmic agent, for life-threatening refractory ventricular tachyarrhythmias: post-marketing special investigation. Circ J. 2005;69:1237\u201343.","journal-title":"Circ J"},{"key":"369_CR5","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1253\/jcj.65.60","volume":"65","author":"K Takenaka","year":"2001","unstructured":"Takenaka K, Yasuda S, Miyazaki S, Kurita T, Sutani Y, Morii I, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J. 2001;65:60\u20132.","journal-title":"Jpn Circ J"},{"key":"369_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1023\/A:1012723101831","volume":"15","author":"T Koizumi","year":"2001","unstructured":"Koizumi T, Komiyama N, Komuro I, Tanigawa T, Iwase T, Ishiwata S, et al. Efficacy of nifekalant hydrochloride on the treatment of life-threatening ventricular tachyarrhythmias during reperfusion for acute myocardial infarction. Cardiovasc Drugs Ther. 2001;15:363\u20135.","journal-title":"Cardiovasc Drugs Ther"},{"key":"369_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1536\/jhj.45.691","volume":"45","author":"K Kokaji","year":"2004","unstructured":"Kokaji K, Okamoto M, Hotoda K, Kumamaru H. Experience with nifekalant hydrochloride in a patient with ischemic cardiomyopathy and severe ventricular dysfunction after Dor operation. Jpn Heart J. 2004;45:691\u20135.","journal-title":"Jpn Heart J"},{"key":"369_CR8","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.athoracsur.2009.09.087","volume":"89","author":"K Kurisu","year":"2010","unstructured":"Kurisu K, Hisahara M, Onitsuka H, Sekiya M, Ikeuchi M, Kozai T, et al. Nifekalant hydrochloride terminated electrical storms after coronary surgery. Ann Thorac Surg. 2010;89:1637\u20139.","journal-title":"Ann Thorac Surg"},{"key":"369_CR9","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1253\/circj.67.898","volume":"67","author":"M Miyoishi","year":"2003","unstructured":"Miyoishi M, Yasuda S, Miyazaki S, Ueno K, Morii I, Satomi K, Otsuka Y, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhymia in patients with renal failure undergoing hemoedialysis. Circ J. 2003;67:898\u2013900.","journal-title":"Circ J"},{"key":"369_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.5105\/jse.29.10","volume":"29","author":"T Kurita","year":"2009","unstructured":"Kurita T, Noda T, Okamura H, Satomi K, Shimizu K, Suyama K, et al. Clinical use of lintavenous lidocaine, nifelalant and amiodarone for management of lethal arrhythmias. The efficacy and the adverse effect of intravenous nifekalant. Jpn J Electrocardiology. 2009;29:10\u20137.","journal-title":"Jpn J Electrocardiology"}],"container-title":["JA Clinical Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-00369-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40981-020-00369-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40981-020-00369-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T23:07:58Z","timestamp":1628636878000},"score":1,"resource":{"primary":{"URL":"https:\/\/jaclinicalreports.springeropen.com\/articles\/10.1186\/s40981-020-00369-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,11]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["369"],"URL":"https:\/\/doi.org\/10.1186\/s40981-020-00369-w","relation":{},"ISSN":["2363-9024"],"issn-type":[{"type":"electronic","value":"2363-9024"}],"subject":[],"published":{"date-parts":[[2020,8,11]]},"assertion":[{"value":"4 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In our institution, the publication of case reports is exempted from ethics committee approval.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The patient provided written permission for the authors to publish the report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"60"}}